Literature DB >> 10992443

Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.

S P Sambol1, M M Merrigan, D Lyerly, D N Gerding, S Johnson.   

Abstract

A toxin variant strain of Clostridium difficile was isolated from two patients with C. difficile-associated disease (CDAD), one of whom died from extensive pseudomembranous colitis. This strain, identified by restriction endonuclease analysis (REA) as type CF2, was not detected by an immunoassay for C. difficile toxin A. Culture supernatants of CF2 failed to elicit significant enterotoxic activity in the rabbit ileal loop assay but did produce atypical cytopathic effects in cell culture assay. Southern hybridization, PCR amplification, and DNA sequence analyses were performed on the toxin A (tcdA) and toxin B (tcdB) genes of type CF2 isolate 5340. Type CF2 5340 tcdA exhibited a 1,821-bp truncation, due to three deletions in the 3' end of the gene, and a point mutation in the 5' end of the gene, resulting in a premature stop codon at tcdA position 139. Type CF2 5340 tcdB exhibited multiple nucleotide base substitutions in the 5' end of the gene compared to tcdB of the standard toxigenic strain VPI 10463. Type CF2 5340 toxin gene nucleotide sequences and deduced amino acid sequences showed a strong resemblance to those of the previously described variant C. difficile strain 1470, a strain reported to have reduced pathogenicity and no association with clinical illness in humans. REA of strain 1470 identified this strain as a distinct type (CF1) within the same REA group as the closely related type CF2. A review of our clinical-isolate collection identified five additional patients infected with type CF2, three of whom had documented CDAD. PCR amplification of the 3' end of tcdA demonstrated identical 1. 8-kb deletions in all seven type CF2 isolates. REA type CF2 is a toxin variant strain of C. difficile that retains the ability to cause disease in humans but is not detected in clinical immunoassays for toxin A.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992443      PMCID: PMC101495          DOI: 10.1128/IAI.68.10.5480-5487.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Growth of Clostridium difficile and production of toxins A and B in complex and defined media.

Authors:  S C Haslam; J M Ketley; T J Mitchell; J Stephen; D W Burdon; D C Candy
Journal:  J Med Microbiol       Date:  1986-06       Impact factor: 2.472

3.  Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study.

Authors:  D N Gerding; M M Olson; L R Peterson; D G Teasley; R L Gebhard; M L Schwartz; J T Lee
Journal:  Arch Intern Med       Date:  1986-01

4.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

5.  Purification and characterization of toxins A and B of Clostridium difficile.

Authors:  N M Sullivan; S Pellett; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

6.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

7.  A nonsense mutation abrogates production of a functional enterotoxin A in Clostridium difficile toxinotype VIII strains of serogroups F and X.

Authors:  C von Eichel-Streiber; I Zec-Pirnat; M Grabnar; M Rupnik
Journal:  FEMS Microbiol Lett       Date:  1999-09-01       Impact factor: 2.742

8.  Prospective study of gram-stained stool smears in diagnosis of Clostridium difficile colitis.

Authors:  C J Shanholtzer; L R Peterson; M N Olson; D N Gerding
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948

9.  Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; N Moon; T W Chang; N Taylor; A B Onderdonk
Journal:  Gastroenterology       Date:  1978-11       Impact factor: 22.682

10.  Effects of Clostridium difficile toxins given intragastrically to animals.

Authors:  D M Lyerly; K E Saum; D K MacDonald; T D Wilkins
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

View more
  28 in total

1.  A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.

Authors:  Zhiyong Yang; Diane Schmidt; Weilong Liu; Shan Li; Lianfa Shi; Jinliang Sheng; Kevin Chen; Hua Yu; Jacqueline M Tremblay; Xinhua Chen; Kurt H Piepenbrink; Eric J Sundberg; Ciaran P Kelly; Guang Bai; Charles B Shoemaker; Hanping Feng
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

Review 2.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Utilizing case reports to build awareness of rare complications in critical care.

Authors:  Rachel R Walden; Rebecca N Jerome; Richard S Miller
Journal:  J Med Libr Assoc       Date:  2007-01

4.  Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.

Authors:  S W Pawlowski; G Calabrese; G L Kolling; J Platts-Mills; R Freire; C AlcantaraWarren; B Liu; R B Sartor; R L Guerrant
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

5.  Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.

Authors:  Jason G S Ho; Antonio Greco; Maja Rupnik; Kenneth K-S Ng
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

6.  Clostridium difficile infection: risk factors, diagnosis and management.

Authors:  Christina M Surawicz
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

7.  Application of isothermal helicase-dependent amplification with a disposable detection device in a simple sensitive stool test for toxigenic Clostridium difficile.

Authors:  Wing Huen A Chow; Cindy McCloskey; Yanhong Tong; Lin Hu; Qimin You; Ciarán P Kelly; Huimin Kong; Yi-Wei Tang; Wen Tang
Journal:  J Mol Diagn       Date:  2008-07-31       Impact factor: 5.568

8.  Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restriction endonuclease analysis.

Authors:  Jane W Marsh; Mary M O'Leary; Kathleen A Shutt; Susan P Sambol; Stuart Johnson; Dale N Gerding; Lee H Harrison
Journal:  J Clin Microbiol       Date:  2009-12-02       Impact factor: 5.948

9.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  Characterisation of Clostridium difficile strains isolated from Groote Schuur Hospital, Cape Town, South Africa.

Authors:  B Kullin; T Brock; N Rajabally; F Anwar; G Vedantam; S Reid; V Abratt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.